. .

Notfalltelefon: 089 3068 2589

E-Mail: Kinderklinik(at)lrz.tum.de

Sie sind hier:  Home  > Forschung & Lehre  > Forschungsgruppen  > Onkologie  > Tumorimmunologie

Klinische Kooperationsgruppe Pädiatrische Tumorimmunologie

Leiter
Univ.-Prof. Dr. med. Uta Behrends
PD Dr. rer. nat. Josef Mautner (stellv.)


Adressen
1) Kinderklinik der Technischen Universität München
Klinikum Schwabing, Kölner Platz 1, 80804 München
Tel.: 089/ 3068 3412, Fax.: 089/ 3068 3811     

2) KKG Pädiatrische Tumorimmunologie, Abteilung Genvektoren
Helmholtz Zentrum München, Hämatologikum, Ebene 02
Marchioninistrasse 25, 81377 München
Tel.: 089/ 3187 1518, Fax.: 089/ 3187 4225
E-mail: uta.behrends(at)lrz.tum.demautner@helmholtz-muenchen.de  


Arbeitsthema
Herpesviren & Immundysregulation im Kindesalter


Schwerpunkte
Epstein-Barr-Virus (EBV), CD4+ T-Lymphozyten, Antigenpräsentation


Projekte
1) Analyse Herpesvirus-spezifischer Immmunantworten bei Immungesunden und Patienten mit Immundefekt, Autoimmunerkrankung oder EBV-assoziiertem Malignom
2) Entwicklung neuer Ansätze für die Diagnostik & Therapie EBV-assoziierter Erkrankungen
3) Analyse der Immunmodulation im Kontext EBV-assoziierter Erkrankungen
4) Identifikation von MHC-Klasse-II-restringierten Antigenen
5) Mechanistische Analyse der Antigenpräsentation auf MHC-Klasse-II


Drittmittel
Helmholtz Znetrum München (HMGU)Deutsches Zentrum für Infektionsforschung (DZIF)Deutsche Forschungsgemeinschaft (DFG)Deutsche Jose Carreras Leukämie-Stiftung (DJCLS)Elterninitiative krebskranke Kinder e.V.


Kooperationspartner

Abteilung Genvektoren, HMGU, München (W. Hammerschidt, A. Moosmann)
Deutsches Krebsforschungszentrum, DKFZ, Heidelberg (JH Delecluse, R Feederle)
Institut für Virologie, TUM & HMGU, München (U. Protzer, T. Bauer)
Institut für Mikrobiologie und Hygiene, TUM München (D. Busch)
Institut für Virologie, LMU, München (J. Jäger)
Institut für Transfusionsmedizin, LMU, München (K. Witter)
NHL-Studien der GPOH, Gießen/Münster (B Burkardt/W. Wößmann)
pedPTLD-Studien der GPOH, Hannover (B. Maecker)
HLH-Studien der GPOH, Kiel (G Janka, K Lehmberg)
CCI, Freiburg (S. Ehl)
Lymphknotenregister, Kiel (W. Klapper)
Münchner Kinderkliniken & Kinderarztpraxen


Publikationen 2003 - 2013
Presentation of an immunodominant immediate-early CD8+ T cell epitope resists human cytomegalovirus immunoevasion. Ameres S et al., PLoS Pathog. 2013;9:e1003383. 
Isolation of human MHC class II-restricted T cell receptors from the autologous T-cell repertoire with potent anti-leukaemic reactivity. Weigand LU et al., Immunology. 2012;137:226-38.
Mature proteins derived from Epstein-Barr virus fail to feed into the MHC class I antigenic pool. Fiebiger BM et al. Eur J Immunol. 2012;42:3167-73.
Humanized c-Myc mouse. Lehmann FM et al., PLoS One. 2012;7:e42021.
Burkitt lymphoma: the role of Epstein-Barr virus revisited. Grömminger S et al., Br J Haematol. 2012;156:719-29. Review.
Stromal interferon-γ signaling and cross-presentation are required to eliminate antigen-loss variants of B cell lymphomas in mice. Gerbitz A et al., PLoS One. 2012;7:e34552.
The role of virus-specific CD4+ T cells in the control of Epstein-Barr virus infection.Mautner J & Bornkamm GW. Eur J Cell Biol. 2012;91:31-5. 
Autophagy in herpesvirus immune control and immune escape. Taylor GS et al., Herpesviridae. 2011;2:2.
Pancreatic cancers require autophagy for tumor growth. Yang S et al., Genes Dev. 2011;25:717-29.
Identification of MHC II-restricted minor histocompatibility antigens after HLA-identical stem-cell transplantation. Milosevic S et al., Transplantation. 2010;90:1030-5.
Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors. Merlo A et al., J Immunol. 2010;184:5895-902.
Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells.Moosmann A et al., Blood. 2010;115:2960-70.
Epstein-Barr viruses that express a CD21 antibody provide evidence that gp350's functions extend beyond B-cell surface binding. Busse C et al., J Virol. 2010;84:1139-47.
An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link.
Kelly GL et al., PLoS Pathog. 2009;5:e1000341.
Primary B-cell infection with a deltaBALF4 Epstein-Barr virus comes to a halt in the endosomal compartment yet still elicits a potent CD4-positive cytotoxic T-cell response. Neuhierl B et al. J Virol. 2009;83:4616-23.
Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells.
Klibi J et al., Blood. 2009;113:1957-66. Erratum in: Blood. 2009;114:3974.
Contribution of viral recombinants to the study of the immune response against the Epstein-Barr virus. Delecluse HJ et al., Semin Cancer Biol. 2008;18:409-15. Review.
Endogenous presentation of a nuclear antigen on MHC class II by autophagy in the absence of CRM1-mediated nuclear export. Riedel A et al., Eur J Immunol. 2008;38:2090-5. 
Standardized and highly efficient expansion of Epstein-Barr virus-specific CD4+ T cells by using virus-like particles. Adhikary D et al., J Virol. 2008;82:3903-11.
A novel HLA-DRB1 allele, HLA-DRB1*0465, was identified in a Hodgkin's lymphoma cell line. Witter K et al., Tissue Antigens. 2008;71:257-8. 
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Klionsky DJ et al. , Autophagy. 2008;4:151-75. Review.
Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy. Adhikary D, Behrends U, Boerschmann H, Pfünder A, Burdach S, Moosmann A, Witter K, Bornkamm GW, Mautner J. PLoS One. 2007;2:e583. Review.
HLA-DQB1*0319, a novel HLA-DQB1 allele, shows strong haplotype association to HLA-DRB1*1102. Witter K et al., Tissue Antigens. 2007;70:73-5.
Identification of major histocompatibility complex class II-restricted antigens and epitopes of the Epstein-Barr virus by a novel bacterial expression cloning approach.Milosevic S et al., J Virol. 2006;80:10357-64.
Epstein-Barr virus BNRF1 protein allows efficient transfer from the endosomal compartment to the nucleus of primary B lymphocytes. Feederle R et al., J Virol. 2006;80:9435-43.
The infectious kiss: newly infected B cells deliver Epstein-Barr virus to epithelial cells.Bornkamm GW et al., Proc Natl Acad Sci U S A. 2006;103:7201-2.
Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. Adhikary D et al., J Exp Med. 2006;203:995-1006.
Direct mapping of MHC class II epitopes. Milosevic S et al., J Immunol Methods. 2005;306:28-39.
Stringent doxycycline-dependent control of gene activities using an episomal one-vector system. Bornkamm GW et al.,  Nucleic Acids Res. 2005;33:e137.
Epstein-Barr virus vector-mediated gene transfer into human B cells: potential for antitumor vaccination. Hellebrand E et al., Gene Ther. 2006;13:150-62.
Epstein-Barr virus latent membrane protein 2A mimics B-cell receptor-dependent virus reactivation. Schaadt E et al., J Gen Virol. 2005;86:551-9.
Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine. Zhou X et al., Cancer Res. 2005;65:1079-88.
Tumor-specific CD4+ T cells from a patient with renal cell carcinoma recognize diverse shared antigens. Mautner J et al., Int J Cancer. 2005;115:752-9.
Epstein-Barr virus nuclear antigen 1 evades direct immune recognition by CD4+ T helper cells. Mautner J et al., Eur J Immunol. 2004;34:2500-9.
Active NF-kappaB signalling is a prerequisite for influenza virus infection. Nimmerjahn F et al., J Gen Virol. 2004;85:2347-56.
Efficient generation and expansion of antigen-specific CD4+ T cells by recombinant influenza viruses. Nimmerjahn F et al., Eur J Immunol. 2003;33:3331-41.
Novel tumor antigens identified by autologous antibody screening of childhood medulloblastoma cDNA libraries. Behrends U et al., Int J Cancer. 2003;106:244-51.
Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy. Nimmerjahn F et al., Eur J Immunol. 2003;33:1250-9.